

CIPRODEX - (0.3%; 0.1%; Suspension/Drops, Otic)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | CIPROFLOXACIN; DEXAMETHASONE | Innovator | Novartis |
| Dosage | 0.3%; 0.1%; Suspension/Drops, Otic | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions of Acute Otitis Media and Acute Otitis Externa. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.